National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

    NEXT STORY
    BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
    PREV STORY
    Roche ranked as one of the most sustainable healthcare companies in the Dow Jones Sustainability Indices for the eleventh year running
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products

    Provides Significant Non-Dilutive Funding to Execute R&D Strategy Sharpens Focus on Proprietary ADAPTIR™ Protein ...

    author_avatar
    NASDAQ Market News

    Precision Therapeutics Investee, Helomics Corporation, Announces Commercial Launch of New ‘HelomicsDiscover’ Program to Drive Forward the Next Generation of Precision Cancer Therapies

    MINNEAPOLIS, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or ...

    author_avatar
    NASDAQ Market News

    New Trump Administration Rules to Increase Patient Options Are Welcome Relief, States the Association of American Physicians and Surgeons (AAPS)

    TUCSON, Ariz., Aug. 02, 2018 (GLOBE NEWSWIRE) -- The Association of American Physicians and ...

    author_avatar
    NASDAQ Market News